IQoro making strides into new international markets
World Health Day, 7th April: New Swedish treatment can improve quality of life for millions
More and more people are discovering the benefits of IQoro. Internationally too, with the markets in Finland, Norway and United Kingdom showing special interest.
“There has never been a simple and effective treatment for dysphagia, nor for common problems such as hiatus hernia, snoring and sleep apnoea. Thanks to IQoro, more people than ever can regain their former quality of life in a natural way”, says Ylvali Gerling, CEO for MYoroface.
Ylvali Gerling, CEO, and Linn Hägg, marketing and sales director at MYoroface. Photo by: Philippe Rendu
At MYoroface, the company behind the neuromuscular treatment method IQoro, there is a targeted project underway to explain to the world that there is a simple way back to wellbeing. The company’s treatment method has created huge awareness in the UK. With 64 million inhabitants, and 1.2 million stroke survivors, of which many are in need of treatment for dysphagia – eating and swallowing difficulties - it is both a large and well-informed market.
Terry Morris, Business Development Director at MYoroface, is focused directly on the British market.
“In the UK, dysphagia and hiatus hernia are well-known problems in the population. There, as in Sweden and many other countries, there is a shortage of effective treatment methods. We know as well, that our treatment method addresses other problems controlled by the same neuromuscular functions in the brain”, he says.
To gain entry in new markets demands a lot. In the UK, the National Institute for Health and Care Excellence (NICE), is evaluating IQoro. The first large-scale service evaluations are now in planning or underway in National Health Service (NHS) hospitals. These evaluations will show how the treatment can be used in general healthcare in the UK. So far, all responses have been positive.
In Norway, IQoro is a listed product in NAV – the national insurance authority - for treatment of children with dysphagia. MYoroface have conducted advanced training for speech and language therapists from Denmark and Norway, and this has formed the basis for sales to hospitals, and to speech and language therapists and dieticians in private practice. In Finland, the company is dealing with enquiries from both distributors and private pharmacies that are interested in selling IQoro.
But it is e-commerce that is driving the fastest expansion at the moment, with sales to private individuals across all of Europe.
“We still have some pieces of the puzzle to get in place to provide a full service to our neighbouring countries. For example, multi-language manuals, and smooth logistics and payment methods; but we are working on it,” says Ylvali Gerling, CEO.
Training with IQoro strengthens the musculature that you can’t exercise voluntarily, and with scientifically proven effect. To activate these muscles, signals are required to go back and forth to the brain. IQoro activates - via the natural communication paths from the mouth to the brain - the muscles in the face, oral cavity, pharynx, esophagus, and down to the diaphragm and stomach. All that is needed is 1½ minutes’ training per day. In this way IQoro treats the root causes behind problems such as swallowing difficulties after stroke, or problems caused by hiatus hernia, snoring and sleep apnoea.
Read more at: https://www.iqoro.com
For more information, contact:
Ylvali Gerling, CEO, MYoroface
+46 (0)70 344 56 65 email@example.com
Terry W. Morris, Business Development Director
+44 (0)7518 511 620 firstname.lastname@example.org